Copper Overload Pushes Cells Toward Death in Wilson Disease

Wilson disease has long been understood as a disorder of copper, a metal the body needs in trace amounts but cannot afford to accumulate. A new review published in Cell Death & Discovery brings together evidence that the lethal cascade triggered by excess copper in this condition runs far deeper than simple metal toxicity. The work examines how copper dyshomeostasis, mitochondrial dysfunction and multiple forms of regulated cell death intertwine in Wilson disease, and argues that this triad should now be treated as the central framework for understanding the illness and designing new therapies. The synthesis arrives at a moment when the field is rapidly redefining how metals kill cells, with the discovery of copper-dependent cell death pathways reshaping long-held assumptions about hepatic and neurological degeneration.

Wilson disease is caused by inherited loss-of-function mutations in the ATP7B gene, which encodes a copper-transporting ATPase responsible for loading copper onto ceruloplasmin in the liver and for excreting surplus copper into bile. When ATP7B fails, dietary copper that would normally leave the body through the biliary route instead accumulates in hepatocytes, eventually spilling into the bloodstream and depositing in the brain, cornea, kidneys and other organs. Clinical presentation is notoriously variable, ranging from acute liver failure in children and young adults to tremor, dystonia, psychiatric disturbance and cognitive decline later in life. The classic Kayser-Fleischer rings in the cornea remain one of the most recognizable diagnostic signs, but the underlying cellular events that convert copper overload into organ failure have remained only partially mapped.

The review emphasizes that copper’s dual role as an essential cofactor and a potent toxin hinges on concentration and chemical speciation. In controlled amounts, copper supports enzymes involved in respiration, antioxidant defense, iron metabolism, neurotransmitter synthesis and connective tissue cross-linking. In excess, particularly in the loosely bound, labile form that accumulates when buffering proteins such as metallothioneins are overwhelmed, copper catalyzes the generation of reactive oxygen species through Fenton-like chemistry. This oxidative burst damages lipids, proteins and DNA, and it is the mitochondria, the cell’s energy factories and major sites of copper-sensitive respiratory function, that emerge as a primary battleground in the disease process.

Mitochondrial dysfunction occupies a central position in the pathogenic model the authors assemble. Copper overload impairs the respiratory chain, disrupts mitochondrial membrane potential, distorts the ultrastructure of cristae and interferes with the metabolic enzymes that carry out the citric acid cycle and oxidative phosphorylation. Studies in animal models of Wilson disease, including the toxic milk mouse and the Long-Evans Cinnamon rat, have documented mitochondrial swelling and respiratory defects that precede overt liver failure. In patients, mitochondrial abnormalities have been observed in hepatocytes and in neural tissue, providing a mechanistic bridge between the biochemical burden of copper and the energetic collapse that marks end-stage disease. Because mitochondria also serve as decision-making hubs for cell death signaling, their compromise does not merely reduce energy output; it actively initiates the programs that dismantle the cell.

Perhaps the most consequential theme in the review is the concept of regulated cell death, the family of genetically encoded, signalable demise pathways that include apoptosis, necroptosis, ferroptosis and the recently described copper-dependent process known as cuproptosis. Classical descriptions of copper toxicity in Wilson disease leaned heavily on nonspecific necrosis, but the field now recognizes that dying hepatocytes and neurons deploy ordered molecular machinery. Apoptosis, driven by mitochondrial outer membrane permeabilization and caspase activation, has been documented in copper-loaded liver tissue. Necroptosis, an inflammatory form of regulated death mediated by the RIPK1-RIPK3-MLKL axis, offers a plausible route by which copper-stressed liver tissue recruits immune cells and amplifies damage. Ferroptosis, an iron-dependent lipid peroxidation-driven death modality, is closely linked to the oxidative stress that copper overload generates, and glutathione depletion, a recurring biochemical finding in Wilson disease, removes a key cellular defense against it.

Cuproptosis deserves particular attention in this framework. Identified as a distinct form of regulated cell death, it depends on copper binding to lipoylated components of the tricarboxylic acid cycle, causing those proteins to aggregate and triggering proteotoxic stress that culminates in cell death. Because the pathway is intrinsically mitochondrial and metabolic, it connects the two other pillars of the review’s thesis: copper excess and mitochondrial dysfunction. Whether cuproptosis is the dominant death pathway in Wilson disease hepatocytes or one contributor among several remains an open question, and the authors are careful to frame it as a hypothesis-generating link rather than a settled fact. Still, the convergence is striking. A disease defined by copper retention, a cell death modality defined by copper sensitivity, and an organelle whose failure characterizes both.

The neurological dimension of Wilson disease adds another layer of complexity. The brain is exquisitely sensitive to metal imbalance, and copper accumulation in the basal ganglia and other regions contributes to the movement disorders and neuropsychiatric symptoms that define the neurologic form of the illness. Neurons face the same oxidative and mitochondrial threats as hepatocytes, but with less regenerative capacity and with additional vulnerabilities, including disruption of copper-dependent enzymes involved in neurotransmitter metabolism and myelination. The review highlights how glial cells, particularly astrocytes, participate in copper handling in the brain and how their dysfunction may propagate injury to neurons. Understanding whether the same regulated death pathways operate in neural tissue as in the liver is an important direction for future research, with direct implications for the roughly half of patients who present with or develop neurological disease.

Therapeutically, the framework has immediate relevance. Standard treatment for Wilson disease has rested for decades on two strategies: chelation therapy with drugs such as penicillamine and trientine, which bind copper and promote its urinary excretion, and zinc salts, which block intestinal copper absorption and induce metallothionein in enterocytes. These approaches are effective for many patients but are limited by side effects, the risk of neurological worsening during initial chelation, and the irreversibility of some established damage. The review’s synthesis suggests new targets. If mitochondrial dysfunction is a proximate driver of cell death, then mitochondria-protective agents, antioxidants and modulators of mitochondrial quality control could complement copper-lowering therapy. If specific death pathways such as necroptosis or ferroptosis are activated, their molecular regulators become candidate drug targets, an approach already being explored in other liver diseases. The authors also point to gene therapy and mRNA-based strategies aimed at restoring functional ATP7B, several of which are in preclinical and early clinical development, as interventions that address the root cause rather than downstream consequences.

Biomarker development is another area the review identifies as ripe for progress. Current monitoring relies on serum copper and ceruloplasmin, 24-hour urinary copper excretion and non-ceruloplasmin-bound copper measurements, none of which perfectly reflect intracellular copper burden or the activity of the death pathways that matter most in tissue. Reliable markers of mitochondrial injury, lipid peroxidation or regulated cell death activation in accessible biofluids would allow clinicians to gauge disease activity more precisely and to evaluate new therapies more efficiently. Research into copper-sensitive probes and imaging approaches may eventually permit noninvasive assessment of metal distribution in liver and brain, transforming both diagnosis and treatment monitoring.

The broader significance of the review extends beyond a single rare disease. Wilson disease has historically served as a model for understanding copper biology in general, and insights gained from it inform research on common conditions in which copper dysregulation has been implicated, including neurodegenerative disorders, cancer and non-alcoholic fatty liver disease. The recognition that metals can execute cells through dedicated death pathways has opened a field that now spans toxicology, cell biology and therapeutics. By situating Wilson disease within this landscape, the authors argue that the condition should be viewed not merely as a storage disorder to be drained, but as a systems-level failure of metal homeostasis, mitochondrial integrity and cell death control. For patients, the hope is that this integrated view will accelerate the translation of molecular discoveries into treatments that protect cells before the point of no return is crossed, preserving both liver function and the neurological health on which quality of life depends.

Subject of Research: Copper dyshomeostasis, mitochondrial dysfunction and regulated cell death pathways in Wilson disease

Article Title: Copper dyshomeostasis, mitochondrial dysfunction, and regulated cell death in Wilson disease

Article References: Qian, N., Xi, H., Song, Y., Li, J., Yang, Y., Rao, Z., Zhai, S., He, W., Qin, G., Cheng, T., & Yang, W. (2026). Copper dyshomeostasis, mitochondrial dysfunction, and regulated cell death in Wilson disease. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03361-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03361-y

Keywords: Wilson disease, copper dyshomeostasis, ATP7B, mitochondrial dysfunction, cuproptosis, regulated cell death, apoptosis, necroptosis, ferroptosis, hepatic copper accumulation, chelation therapy, gene therapy